This analysis examines the current position and future outlook for Akzo Nobel in the ethical pharmaceutical sector. The profile encompasses global and US company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive analysis tool provides continually updated quantitative and qualitative information

• Learn how Akzo plans to recover from the loss of its key product Remeron, through licensing deals and a more efficient, realigned therapeutic focus
• Benchmark Akzo's performance against key rivals in the ethical pharmaceutical sector
• Understand Akzo's strategy to strengthen its position in the rapidly-changing women's health marketplace with novel products